Setmelanotide reduced BMI by at least 5% at 16 weeks among 89% of children and adults with hypothalamic obesity, according to findings from a phase 2 trial published in The Lancet Diabetes ...

Rhythm Pharmaceuticals (RYTM) announced the presentation of new, real-world data that showed four pediatric patients with acquired hypothalamic obesity or congenital hypothalamic obesity achieved ...

Shares of Rhythm Pharmaceuticals RYTM were up 36.6% yesterday after it reported positive top-line data from a phase II study evaluating the investigational oral melanocortin-4 receptor (MC4R) agonist, ...

TOPLINE: Setmelanotide treatment over a 16-week period leads to a consistent decrease in both bodyweight and hunger among patients with hypothalamic obesity, according to the results of the first ...

SAN FRANCISCO — In patients with acquired hypothalamic obesity, setmelanotide reduced BMI at 52 weeks compared with placebo, according to results of the TRANSCEND trial presented at ENDO 2025 ...

The randomized, double-blind, placebo-controlled phase 3 TRANSCEND trial (ClinicalTrials.gov Identifier: NCT05774756) evaluated the efficacy and safety of setmelanotide in 120 patients aged 4 ...

An approval of Imcivree in hypothalamic obesity would be the first for this drug in an acquired form of obesity. It could also potentially become the first approved treatment for this specific ...

The company estimates there are 5,000 to 10,000 people living with hypothalamic obesity in the U.S.

Setmelanotide was associated with significant weight reduction among patients aged 4 years and older with acquired hypothalamic obesity.

GlobeNewswire Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity ...

Dec. 31, 2013 -- A Texas girl is fighting to stay healthy after complications from a brain tumor left her constantly hungry. Alexis Shapiro, 12, suffers from a rare condition called hypothalamic ...